Fisiopatologia della disfunzione epatica nel diabete di tipo 2: nuovi biomarker di rischio e/o patologia

摘要: New biomarker determination in Type 2 Diabetes(T2D) represents a new perspective the development of drugs and further therapeutics approaches: their identification can have great importance for early diagnosis potentially lead to therapies avoid onset type diabetes Our study focused on High Mobility Group Box 1(HMGB1), because our laboratory, by using proteomic techniques, we previously showed that HMGB1 is differently expressed hepatocytes WT(Hep WT) insulin receptor knock out (IRKO) hepatocytes. HMGB1 chromatin-linked non-histonic protein has dual function depending cellular condition: basal condition, inside nucleus helps interaction transcriptional factors with DNA, however an inflammatory condition it secreted into extracellular space acts as pro-inflammatory cytokine. Using murine Hep WT IRKO models performed some treatments reproduce Diabetes pathological conditions: hyperglycemia (Glucose 30mM), Diabetes-related complications (Glucosamine 7.5 mM), obesity (Oleic acid 0.66mM and/or Palmitic 0.33 chronic state (TNF-alpha 100ng/mL). In under stress condition; this secretion much higher than IRKO. Treatment Glucose does not induce HMGB1: data support hypothetical functionality. Under experimental conditions, produce more Reactive Oxygen Species(ROS) do are also sensitive apoptosis. Our dosage human sera. In particular concentrated diabetic patients well diabetics non alcoholic steatosis. Both these groups received treatment at PTV. We experiments 51 cohort, demonstrated there inverse correlation between hepatic This despite direct steatosis all following: secretion, CRP gamma GT